Treatment Adherence and Patient Support in mCSPC

In, ‘Treatment Adherence and Patient Support in mCSPC,’ our panel explores the critical role of treatment adherence, patient engagement, and care coordination in optimizing outcomes for patients with metastatic castration-sensitive prostate cancer (mCSPC). The expert faculty discuss how the expanding treatment landscape continues to evolve while highlighting the practical challenges associated with ensuring patients remain on therapy over time. The discussion begins with a review of how emerging therapies may influence future treatment algorithms. The panel notes that while new combinations and targeted approaches are generating excitement, clinicians must carefully integrate evolving evidence into practice while maintaining established standards of care. The panelists emphasize that future treatment decisions will become increasingly complex as additional therapeutic partnerships and biomarker-driven strategies enter the mCSPC landscape.

The conversation then shifts to treatment adherence and its direct relationship to patient outcomes. The expert faculty highlight that even the most effective therapies cannot achieve their intended benefits if patients are unable to take them consistently. They discuss strategies used within their practices to promote adherence, including patient education at treatment initiation, frequent follow-up visits, toxicity monitoring, pharmacy engagement, and multidisciplinary support programs.

The panel also describes the value of structured patient-management pathways that provide ongoing monitoring throughout treatment. Regular touchpoints with advanced practice providers, pharmacists, and patient navigators help identify barriers to adherence, address adverse events early, and ensure timely medication refills. The panel underscores that successful mCSPC management extends beyond selecting the appropriate therapy and requires comprehensive systems to support long-term treatment adherence and patient-centered care.

Our next episode, ‘Monitoring Treatment Response in mCSPC,’ examines how the panel monitors patients receiving doublet therapy using PSA assessments, imaging, laboratory testing, and clinical evaluation. The panelists discuss strategies for identifying disease progression early, the role of routine imaging, and the challenges associated with monitoring patients in real-world practice.